Publishing: July 2021 | Report Code: LS12190 | Available Format: PDF
The global active pharmaceutical ingredient market stood at around $190 billion in 2020, and it is expected to reach approximately $300 billion by 2030. This can be attributed to the widening of the application area of drugs, expiration of patented biologics, increase in the incidence of chronic and lifestyle-associated diseases, such as cancer, diabetes, and cardiovascular diseases, rise in the geriatric population, government initiatives to promote generic drugs, investments in biosimilars, increasing healthcare expenditure, and surging awareness about diseases.
Due to the COVID-19 pandemic, lockdowns were imposed by the government in several countries across the world, which disrupted the supply chain and economic activity during the first half of 2020. However, established pharmaceutical and biotech companies, as well as research institutes, stepped forward to develop a treatment against the coronavirus, which had a positive impact on the API market.
The captive category held the larger share in the active pharmaceutical ingredient market during 2015–2020, and it is expected to retain its position in the upcoming years, based on the type of manufacturer. This can be attributed to the easy availability of raw materials and surging investments by the major players to develop high-end manufacturing facilities.
The innovative APIs category held the larger share in the market for active pharmaceutical ingredient during the historical period, based on type, and it is expected to retain its position in the upcoming years. The increasing drug research and development (R&D) initiatives by innovator API companies, favorable government regulations, and launch of novel and more-effective medicines are the key factors contributing to the growth of the innovative APIs category.
The biotech APIs category is expected to expand at the higher CAGR in the upcoming years, based on the type of synthesis. This can be attributed to the high investments in the biotechnology research and biopharmaceutical sectors, adoption of biological therapies for disease management, increasing number of approvals for biologics, and increasing number of branded drugs going off-patent.
The oncology category is expected to register the highest CAGR during the forecast period, based on therapeutic application. This would be driven by the high prevalence of cancer and increasing demand for highly potent APIs (HPAPIs) for its treatment.
Geographically, North America held the largest share in the active pharmaceutical ingredient market in 2020 owing to the rising R&D investments in the area of drugs, improving healthcare infrastructure, and technological advancements in the region.
APAC is expected to witness the fastest growth during the forecast period (2021–2030). This will be due to the large patient pool, surge in the healthcare expenditure, and the existence of a large number of companies manufacturing generic drugs in the region. Additionally, an increasing number of people are becoming aware about lifestyle-associated diseases, which is further driving the industry progress in the region.
Over the past decade, the API market has witnessed a large number of mergers, acquisitions, and partnerships globally. For instance, in August 2020, Pfizer Inc. announced a multi-year agreement with Gilead Sciences Inc. to manufacture and supply the latter’s investigational antiviral remdesivir, in an effort to scale up the supply of the investigational treatment for COVID-19. Additionally, in April 2020, Boehringer Ingelheim International GmbH. acquired Northern Biologics, which focuses on therapeutic antibodies targeting the tumor microenvironment, to combat cancer and other serious diseases. This acquisition broadened Boehringer Ingelheim’s oncology product portfolio.
The increasing life expectancy is a major contributor to the growth in the geriatric population. As per the United Nations Department of Economic and Social Affairs (UNDESA) report World Population Ageing 2019, the population of people aged 65 years or above is projected to double to 1.5 billion by 2050. Globally, the share of this population increased from 6% in 1990 to 9% in 2019, and it is projected to rise further to 16% in 2050. The elderly require extensive care as they need a longer recovery time and are more prone to illnesses owing to their low immunity level. Therefore, to cater to the increasing demand for drugs to treat different diseases and disorders in the elderly, the consumption of APIs is surging.
|Base Year (2020) Market Size||~$190 Billion|
|Market Size Forecast in 2030||~$300 Billion|
|Report Coverage||Market Trends; Drivers; Geographical Insights; Key Players; Segmentation Breakdown|
|Market Size by Segments||By Type of Manufacturer; By Type; By Type of Synthesis; By Therapeutic Application; By Region|
|Market Size of Geographies||U.S., Canada, Germany, France, U.K., Italy, Spain, Japan, China, India, Australia, South Korea, Brazil, Mexico, Saudi Arabia, South Africa|
The active pharmaceutical ingredient market is fragmented, and, hence, in recent years, players have been involved in product launches in order to attain a significant position. For instance,
The global active pharmaceutical ingredient market report offers comprehensive market segmentation analysis along with market estimation for the period 2015–2030.
Based on Manufacturer
Based on Type
Based on Type of Synthesis
Based on Type of Drug
Based on Therapeutic Application
The value of the global API market in 2030 will be $300 billion.
The API industry is growing during the pandemic, due to the increasing research activities being conducted by pharmaceutical companies for developing treatments for COVID-19.
Asia-Pacific (APAC) will be the fastest growing region in the API industry between 2021 and 2030.
The surging geriatric population across the world is the major growth driver of the market for APIs.
Captive manufacturer type category will hold the larger share in the market for APIs between 2021 and 2030.
Get a bespoke market intelligence solution
Our dedication to providing the most-accurate market information has earned us verification by Dun & Bradstreet (D&B). We strive for quality checking of the highest level to enable data-driven decision making for you
Our insights into the minutest levels of the markets, including the latest trends and competitive landscape, give you all the answers you need to take your business to new heights
With 24/7 research support, we ensure that the wheels of your business never stop turning. Don’t let time stand in your way. Get all your queries answered with a simple phone call or email, as and when required
We take a cautious approach to protecting your personal and confidential information. Trust is the strongest bond that connects us and our clients, and trust we build by complying with all international and domestic data protection and privacy laws